Iovance Biotherapeutics IOVA 深 沪
等待开盘 10-03 09:30:00 美东时间
14.215
-0.015
-0.11%
华盛通- 最 高14.75
- 今 开14.45
- 成交量 1191.76万股
- 最 低 13.95
- 昨 收 14.23
- 总市值 64.39亿
- 52周最高 15.30
- 市盈率 静 --
- 换手率 2.63%
- 52周最低 1.76
- 委 比 -36.17%
- 总股本 4.53亿
- 历史最高 54.208
- 量 比 0.40
- 振 幅 5.62%
- 历史最低 1.6385
- 每 手 1
- 风险率 2.38%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Iovance Biotherapeutics Stock Pauses After Hitting New 52-Week High: What's Going On?
Shares of Iovance Biotherapeutics Inc. (NASDAQ:IOVA) are trading flat Wednesday morning, taking a breather after Tuesday’s surge which pushed the stock to a new 52-week high. Here’s what investors need to know. Iovance Biotherapeutics stock is trading at elevated levels. What’s ahead for IOVA stock?...
09-30 22:28
美股牛股 | IOVA劲升31%，上调26年收入指引至4.2亿美元；嘉年华邮轮绩后升逾13%带飞邮轮股，皇家加勒比邮轮升逾7%
IOVA劲升31%，上调26年收入指引至4.2亿美元；嘉年华邮轮升逾13%，Q3业绩超预期；BE升逾10%，Jefferies称大订单及产能扩张支撑其增长>>
09-30 17:18
美股大行评级 | 潜在涨幅11184.05%！如瑞迪博士获花旗上调目标价至1450美元，维持"买入"评级
今日重点评级关注：花旗：上调如瑞迪博士"买入"评级，目标价从1040美元升至1450美元；加拿大帝国商业银行：维持Inventiva"买入"评级，目标价从20美元升至21美元
09-30 08:33
Iovance Biotherapeutics shares are trading higher after the company raised its FY26 revenue guidance.
Iovance Biotherapeutics shares are trading higher after the company raised its FY26 revenue guidance.
09-29 19:58
Iovance rises as 2026 revenue outlook tops analyst consensus
Iovance Biotherapeutics (IOVA) raised its full-year 2026 revenue guidance to $410M-$420M, up from the previous range of $350M-$370M. The new guidance is above the $402.8M analyst consensus. The compan...
09-29 19:44
Iovance Biotherapeutics Raises 2026 Revenue Guidance Outlook
An announcement from Iovance Biotherapeutics ( ($IOVA) ) is now available. On S...
09-29 19:28
Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million
Iovance Biotherapeutics raised its 2026 full-year revenue guidance to $410-$420 million, up $55 million midpoint from the prior $350-$370 million range, driven by strong U.S. demand for Amtagvi and Proleukin. This reflects nearly 60% annual revenue growth. Frederick Vogt, Interim CEO, attributed the increase to record Q2 performance and sustained product demand, with manufacturing efficiency supporting Q3-Q4 revenue visibility. Iovance reported Q...
09-29 11:00
美股大行评级 | Meta获4家机构齐升目标价，最高看至995美元！麦当劳遭6家机构下调，最低看至260美元
今日重点评级关注：Canaccord Genuity：维持Aurora Innovation"买入"评级，目标价从15美元升至17美元；摩根大通：维持皇家加勒比邮轮"超配"评级，目标价从345美元升至394美元
09-25 15:55
Goldman Sachs Reinstates Buy on Iovance Biotherapeutics, Announces $15 Price Target
Goldman Sachs analyst Andrea Newkirk reinstates Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and announces $15 price target.
09-24 21:55
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics, Inc. announced on September 17, 2026, the grant of inducement stock options covering 179,750 shares of its common stock to eighteen new, non-executive employees. The options, granted under the Amended and Restated 2021 Inducement Plan, have an exercise price of $10.02 and vest over three years, with one-third vesting on the first anniversary of the employee’s start date and the remainder vesting quarterly over the next tw...
09-18 21:10
